Michael Skynner Biography and Net Worth

Michael Skynner, Ph.D., is the chief technology officer at Bicycle Therapeutics.

Michael joined Bicycle from Pfizer, where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities, he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, Michael established a discovery performance unit at GlaxoSmithKline (GSK) focused on developing therapeutics targeting inflammatory kinases using an externalized and partnered model with leading European biotechnology companies. In his time at GSK, he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd. (CBT), which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum.

Michael obtained his Ph.D. in biochemistry at Imperial College and is an author on more than 30 peer-reviewed scientific publications.

What is Michael Skynner's net worth?: The estimated net worth of Michael Skynner is at least $877.56 thousand as of April 2nd, 2025. Dr. Skynner owns 122,908 shares of Bicycle Therapeutics stock worth more than $877,563 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Skynner may own. Additionally, Dr. Skynner receives an annual salary of $881,010.00 as CTO at Bicycle Therapeutics. Learn More about Michael Skynner's net worth.
How old is Michael Skynner?: Dr. Skynner is currently 55 years old. There are 6 older executives and no younger executives at Bicycle Therapeutics. The oldest executive at Bicycle Therapeutics is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director, who is 73 years old. Learn More on Michael Skynner's age.
What is Michael Skynner's salary?: As the CTO of Bicycle Therapeutics PLC Sponsored ADR, Dr. Skynner earns $881,010.00 per year. There are 2 executives that earn more than Dr. Skynner. The highest earning executive at Bicycle Therapeutics is Dr. Kevin Lee M.B.A., Ph.D., CEO & Executive Director, who commands a salary of $1,350,000.00 per year. Learn More on Michael Skynner's salary.
How do I contact Michael Skynner?: The corporate mailing address for Dr. Skynner and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Michael Skynner's contact information.
Has Michael Skynner been buying or selling shares of Bicycle Therapeutics?: Michael Skynner has not been actively trading shares of Bicycle Therapeutics in the last ninety days. Most recently, Michael Skynner sold 814 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $8.02, for a transaction totalling $6,528.28. Following the completion of the sale, the chief technology officer now directly owns 122,908 shares of the company's stock, valued at $985,722.16. Learn More on Michael Skynner's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 49,366 shares worth more than $563,681.34. The most recent insider tranaction occured on October, 3rd when CEO Kevin Lee sold 3,231 shares worth more than $27,172.71. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 10/3/2025.

Michael Skynner Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2025	Sell	814	$8.02	$6,528.28	122,908
1/2/2025	Sell	3,287	$14.09	$46,313.83	124,658
10/3/2024	Sell	972	$22.26	$21,636.72	92,945
7/3/2024	Sell	967	$19.64	$18,991.88	93,917
4/3/2024	Sell	955	$23.81	$22,738.55	94,884
7/3/2023	Sell	451	$25.10	$11,320.10	70,924
4/3/2023	Sell	447	$21.11	$9,436.17	71,375

Michael Skynner Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $7.14

$6.96

$7.27

50 Day Range

MA: $7.48

$6.17

$8.87

2 Week Range

Now: $7.14

$6.03

$21.50

Volume

302,559 shs

Average Volume

327,116 shs

Market Capitalization

$495.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Michael Skynner Biography and Net Worth

What is Michael Skynner's net worth?

How old is Michael Skynner?

What is Michael Skynner's salary?

How do I contact Michael Skynner?

Has Michael Skynner been buying or selling shares of Bicycle Therapeutics?

Who are Bicycle Therapeutics' active insiders?

Are insiders buying or selling shares of Bicycle Therapeutics?